In this episode of "What's Up, Doc?", Dr. John Bender and his trusted colleague, Janessa Hanna, discuss the latest FDA ruling that impacts semaglutide and tirzepatide GLP-1 medications. They dive into what this means for patients nationwide, especially in light of the discontinued production of compounded medications during the national shortage. The team also explores emerging options for personalized, compounded preparations to address side effects and shares insights into the evolving pharmaceutical landscape. Stay informed with this crucial update from Miramont Wellness Centers.

🎧Listen to our Podcast 🎧

Spotify: ⁠https://open.spotify.com/show/3yDSFFDkuYhY4mYocsTPjO?si=7721b690782a4a0b⁠ 

ApplePodcasts: ⁠https://podcasts.apple.com/us/podcast/whats-up-doc/id1746818880⁠ 

Learn more about Miramont Wellness Centers.

https://miramont.us⁠ 

Call Us: (970) 225-5000

#SemaglutideUpdates #WeightLossJourney #MiramontWellnessCenters #GLP1 #Ozempic #WeightLossPlateau #Ketosis #SemaglutideAlternative #WellnessPodcast #WhatsUpDoc #FDA #Nationaldrugshortage